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Reduced total energy expenditure and physical activity in cachectic
patients with pancreatic cancer can be modulated by an energy
and protein dense oral supplement enriched with n-3 fatty acids
AWG Moses1, C Slater2, T Preston3, MD Barber1 and KCH Fearon*,1
1Department of Clinical and Surgical Sciences (Surgery), University of Edinburgh, Royal Inf irmary, Little France Crescent, Edinburgh EH16 4SA, UK;
2Division of Developmental Medicine, University of Glasgow, Yorkhill Hospitals, Glasgow G3 8SJ, UK; 3Scottish Universities Environmental Research,
Scottish Enterprise Technology Park, Rankine Avenue, East Kilbride, Glasgow G75 0QF, UK
The aim of the study was to assess the total energy expenditure (TEE), resting energy expenditure (REE) and physical activity level
(PAL) in home-living cachectic patients with advanced pancreatic cancer. The influence of an energy and protein dense oral
supplement either enriched with or without the n-3 fatty acid eicosapentaenoic acid (EPA) and administered over an 8-week period
was also determined. In total, 24 patients were studied at baseline. The total energy expenditure was measured using doubly labelled
water and REE determined by indirect calorimetry. Patients were studied at baseline and then randomised to either oral nutritional
supplement. Measurements were repeated at 8 weeks. At baseline, REE was increased compared with predicted values for healthy
individuals (1387(42) vs 1268(32) kcal day1, P¼ 0.001), but TEE (1732(82) vs 1903(48) kcal day1, P¼ 0.023) and PAL (1.24(0.04)
vs 1.50) were reduced. After 8 weeks, the REE, TEE and PAL of patients who received the control supplement did not change
significantly. In contrast, although REE did not change, TEE and PAL increased significantly in those who received the n-3 (EPA)
enriched supplement. In summary, patients with advanced pancreatic cancer were hypermetabolic. However, TEE was reduced and
this was secondary to a reduction in physical activity. The control energy and protein dense oral supplement did not influence the
physical activity component of TEE. In contrast, administration of the supplement enriched with EPA was associated with an increase
in physical activity, which may reflect improved quality of life.
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Weight loss in cancer is frequently ascribed to a combination of
reduced food intake and hypermetabolism. However, the meta-
bolic response to cancer is heterogeneous. Some patients show an
increase in resting energy expenditure (REE), while others show
either no change or are hypometabolic (Dempsey et al, 1986). It
has been suggested that in cachectic patients with lung cancer,
although REE may be elevated, total energy expenditure (TEE) is
decreased (Gibney et al, 1997). Apart from REE, the major
contributor to TEE is the energy associated with physical activity.
Thus, weight-losing cancer patients appear to reduce the
magnitude of their evident energy deficit by a reduction in
physical activity. Clearly, such a phenomenon will impact on their
quality of life. We have demonstrated previously that patients with
advanced pancreatic cancer have an increased REE (Falconer et al,
1994). However, the effects of pancreatic cancer on TEE and
physical activity level (PAL) are unknown.
The mediators of anorexia and metabolic change in cancer
patients are thought to include proinflammatory cytokines,
neuroendocrine stress hormones and tumour-specific cachectic
factors such as proteolysis-inducing factor (PIF) (Tisdale, 2002).
Eicosapentaenoic acid (EPA) is an n-3 fatty acid, which has been
shown to downregulate proinflammatory cytokine release both in
healthy individuals (Endres et al, 1989) and in cachectic cancer
patients (Wigmore et al 1997; Moses et al, 2002). Eicosapentaenoic
acid has also been shown to inhibit muscle protein catabolism
induced by PIF (Lorite et al, 1997) by inhibiting the activation of
the ubiquitin proteasome pathway (Whitehouse et al, 2001). The
administration of EPA either as fish oil capsules (Wigmore et al,
1996) or in a purified form (Wigmore et al, 2000) to cachectic
cancer patients has been associated with weight stabilisation.
Eicosapentaenoic acid combined with an energy and protein dense
oral supplement has been shown to be associated with increased
lean body mass (LBM), normalisation of elevated REE and
improved performance status (Barber et al, 1999).
The present study was part of a randomised controlled trial
comparing the effects of an EPA containing nutritional supplement
with those of an isocaloric, isonitrogenous control supplement on
weight, LBM and quality of life in patients with pancreatic cancer
cachexia (Fearon et al, 2003). The aim of this particular study was
to determine whether the decreased TEE and PAL observed in lung
cancer patients (Gibney et al, 1997) is also observed in patients
with gastrointestinal (pancreatic) malignancy and to test the
hypothesis that the combination of EPA with an energy and
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protein dense supplement might be associated with stabilisation or
gain in weight and improved TEE/PAL as a potential objective
measure of quality of life.
PATIENTS AND METHODS
Patients
A total of 24 patients with unresectable pancreatic cancer who had
been referred to the Royal Infirmary of Edinburgh were included
in the study if they had lost more than 5% of their preillness stable
weight over the previous 6 months, had a Karnofsky performance
score of 60 or more and had a life expectancy greater than 2
months. Patients’ average survival was, in fact, 130 days from the
time of recruitment. All patients underwent staging by CT scan. In
all, 17 patients had histological proof of diagnosis and seven
patients were diagnosed on the basis of unequivocal clinical
(operative) or radiological (CT scan) findings. In total, 16 patients
underwent laparoscopy and 13 patients underwent laparotomy.
Patients with pancreatic cancer were selected for this study as these
patients usually experience severe weight loss associated with
cancer cachexia. Patients were excluded if they had: undergone
major surgery, endoscopic stenting, radiotherapy or chemotherapy
during the previous 4 weeks; other active medical conditions (e.g.
major gastrointestinal disease, chronic renal failure, uncontrolled
diabetes and human immunodeficiency virus); a body mass index
(BMI) greater than 30 kg m2; received medication that could
profoundly modulate metabolism or weight, in particular, the use
of fish oil or n-3 fatty acid preparations exceeding 200 mg day1
EPA or one capsule of fish oil/day within the previous 90 days. At
the time of enrolment no patient had jaundice, pyrexia, severe
anaemia, clinical or radiological evidence of infection and none
were taking steroids at doses above that for physiological
replacement. No patients had ascites or dependent ankle oedema.
Pancreatic enzyme supplements were administered if patients had
or developed clinical evidence of steatorrhoea. The Lothian Region
Ethics Committee for human research approved the protocol, and
written informed consent was obtained from all patients.
Procedures followed were in accordance with the Helsinki
Declaration of 1975, as revised in 1983.
Study design The study was undertaken at one centre (Royal
Infirmary, Edinburgh) on patients who had also been included in a
multicentre, randomised, double-blind trial (Fearon et al, 2003).
Patients were asked to consume two cans per day of either an n-3
fatty acid containing oral nutritional supplement or an identical
supplement without n-3 fatty acids for an 8-week period. Both oral
supplements were provided by Ross Products Division, Abbott
Laboratories, Columbus, OH, USA and were ready-to-use,
calorically dense, high-protein, low-fat formulations intended to
act as a supplement to the patient’s usual diet. Each 237 ml can
provide 310 kcal, 16 g protein, 6 g fat, with or without 1.1 g of the n-
3 fatty acid, EPA (Barber et al, 1999). The control and experimental
(n-3 enriched) oral supplements were isocaloric and isonitrogen-
ous. The increase in the n-3 fatty acid content of the experimental
supplement was balanced by an increase in the n-9 (oleic) fatty
acid content of the control supplement. Compliance was evaluated
by the supplement consumption records kept daily by patients and
after the blind was broken by measurement of plasma phospho-
lipid EPA levels. Within the multicentre study, patients were
randomised after stratifying for study site and histological proof of
diagnosis to permutation blocks of two using a sequential series of
numbered, sealed, opaque envelopes containing computer-gener-
ated random assignments. A copy of the randomisation sequence
was kept in a locked cabinet not available to study personnel.
Randomisation envelopes were opened by personnel shipping the
product directly to the patients’ homes. The patients, investigators
and study personnel were blinded to the treatment group
allocation. Study products were not distinguishable from each
other in appearance, texture or taste. The blind was broken after all
sample analyses were completed.
At enrolment into the study, the patients’ weight, height and
body composition using bioelectrical impedence were measured.
Over the following 14 days, a doubly labelled water protocol was
followed to measure TEE. A 3-day diet diary was completed during
this period. On day 14 of the protocol, the patients attended the
baseline visit. Resting energy expenditure was measured by
indirect calorimetry. Weight was measured and body composition
analysis was repeated using bioelectrical impedence analysis.
Patients consumed up to two cans per day for the next 8 weeks.
At the start of the 7th week, patients underwent repeat
measurement of TEE using the doubly labelled water protocol
(which ran for 14 days to the end of week 8). A further 3-day diet
diary was completed during this time. At the end of the 8 weeks of
oral supplementation, patients returned for physical examination
and measurement of weight, body composition, REE and plasma
EPA levels.
Weight and body composition
At the initial assessment, preillness stable weight and duration of
weight loss were self-reported. Patients’ height was measured and
they were weighed on spring balance scales (Tanita Solar Powered
Scale Model 1618, Tanita, Uxbridge, Middlesex, UK) without shoes
and wearing light clothing. The same scales were used for
consecutive visits.
Body composition for isotope dosing was assessed using a
Xitron Hydra multiple-frequency bioelectrical impedance analyser
(Xitron Technologies, San Diego, California, USA) as previously
described (Hannan et al, 1995). Resistance was measured at 5 and
200 kHz. Total body water (TBW) was derived using equations
validated in a similar patient group (Hannan et al, 1995). Lean
body mass was calculated assuming that lean tissue contains 73%
water.
Resting energy expenditure
Following an overnight fast, patients attended at 0800. Patients
rested in a supine position for at least 30 min before undergoing
indirect calorimetry using a ventilated hood technique (Deltatrac;
Datex, Helsinki, Finland) (Falconer et al, 1994). This system
provides measurements of VO2 and VCO2, which have an error of
less than 4% (Makita et al, 1990). Measurements were performed
for at least 30 min. The measurements performed in the last 20 min
were averaged to calculate REE using the Weir (1949) equation.
Predicted values for REE were derived from the equations of
Schofield (Schofield, 1985).
Preparation of doubly labelled water
At enrolment, patient’s TBW was derived from the measurements
of height, weight and bioimpedance at 200 kHz (Hannan et al,
1995). The TBW pool was enriched with 2H and 18O to a target
initial concentration of 125 parts per million excess. The weight (g)
of 2H2O required (g) was calculated thus: TBW (kg) 0.125. The
weight of 10 atom% 18O–H2O (g) was calculated thus: TBW
(kg) 1.25. The 2H2O was added to a glass bottle and the weight
was recorded to four decimal places. The H2
18O was then added and
again the weight was recorded to four decimal places. The bottle
was sealed with a plastic cap and parafilm (American National
Can, Menasha, WI, USA via BDH Laboratory Supplies). Prior to
sealing the bottle, a 100 ml aliquot was removed and added to a
preweighed 100-ml glass flask containing 90 ml of tap water, which
was then weighed to four decimal places. The flask was then filled
with tap water to a total volume of 100 ml and then reweighed. The
bottle was thoroughly mixed and a 20 ml aliquot was then added to
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a separate glass bottle, sealed and kept frozen at 201C pending
analysis. A sample of the tap water used for dilution was stored
similarly.
Doubly labelled water protocol
On day 0, the subject collected their second urine sample of the
day and poured an aliquot into a 30 ml glass bottle and
recorded the time. The doubly labelled water was then consumed
by the patient. Thereafter, the bottle that had contained the
labelled water was rinsed with tap water and then the contents
drunk to ensure that all labelled water had been ingested. On days
1, 2, 3, 12, 13 and 14, part of the second urine sample of the
day was transferred to a 30 ml glass bottle and the time was
recorded. All urine samples were sent by post to the laboratory
in preprepared envelopes and on receipt frozen at 201C prior
to analysis.
Analysis of urine samples
2H analysis Samples were prepared according to the method of
Scrimgeour et al (1993). Urine samples were thawed completely,
shaken and centrifuged at 1000 g for 5 min. Samples were prepared
in duplicate. Urine (400 ml) was pipetted into 10 ml Exetainer gas
testing vials (Labco, High Wycombe, Berks); glass inserts (200 ml,
Chromacol, Welwyn Garden City, Herts) containing platinum
catalyst (platinum 5% on alumina powder, 325 surface area
4250 m2 g1, Sigma Aldrich, Gillingham, Dorset) were added to
each vial, taking care not to wet the catalyst. Reference samples
(0 and 75 ppm excess 2H) were prepared and analysed with
each batch. Exetainer vials were placed on a 20-tube manifold and
were evacuated for 1 min. The manifold was brought to
atmospheric pressure prior to flushing with reference gas for
5 min. Samples were filled with reference gas (5% hydrogen in
helium, Air Products Special Gases, Crewe) for 10 s and left to
equilibrate at room temperature for a minimum of 48 h prior
analysis. During this time the deuterium in the water phase
equilibrates with the hydrogen in the gas phase. The abundance of
deuterium in the gas phase was measured using a continuous flow
isotope ratio mass spectrometer (CF-IRMS, Hydra, PDZ Europa,
Crewe) (Prosser and Scrimgeour, 1995), which had been calibrated
against international standards. The abundance of 2H in patient
samples was calculated with reference to the known abundance of
the reference samples.
18O analysis Samples were prepared for 18O analysis according to
the method of Prosser et al (1991). After deuterium analysis, the
samples were refrigerated until required for 18O analysis. Vials
were evacuated as for deuterium analysis and filled with reference
gas (3% CO2 in nitrogen, Air Products Special Gases, Crewe).
Reference samples (0 and 150 ppm excess 18O) were prepared and
analysed with each batch. Samples were left to equilibrate for 24 h
at ambient temperature. The abundance of 18O in the gas phase
was measured by CF-IRMS. The abundance of patients’ samples
was calculated with reference to the known abundance of the
reference samples.
Calculation of TEE
‘Multipoint’ calculations were used to derive turnover rates and
initial enrichments of each isotope, to estimate CO2 production
and TBW, respectively. Schoeller’s equation for estimating TEE
was used in the form given by Goran et al (1994). A resampling
procedure was used to estimate the errors in (TBW) and TEE
measurement (Wolfe, 1992). The precision of TBW analysis was
0.16 kg with 18O (s.d.) and 0.18 kg with 2H. TEE errors estimated by
the resampling procedure averaged 4.8% (0.32 (s.d. 0.17)
MJ day1). Tracer elimination rate was normal (kO/kH¼ 1.279,
s.d. 0.071 and the average 2H : 18O distribution volume or pool
space ratio was 1.0316 (s.d. 0.055). Predicted values for TEE were
derived from predicted REE values (Schofield, 1985) multiplied by
1.5. This prediction derives from the lifestyle category defined as
‘Seated work with no option of moving around and little or no
strenuous activity’ given a PAL range of 1.4–1.5 by Black et al
(1996).
Calculation of PAL
PAL was calculated from the formula PAL¼TEE/REE. A PAL of
1.5 for healthy sedentary adults was derived from the work of Black
et al (1996).
Calculation of energy expenditure of activity (EEA)
EEA was calculated from the formula EEA¼TEEREE. This
definition of EEA includes dietary-induced thermogenesis and
nonexercise activity thermogenesis (Levine et al, 2001)
Dietary intake
A 3-day diet diary completed prior to baseline (week 0), and
during week 8, was used to assess the patients’ dietary intake. A
dietitian instructed patients on how to record food and beverage
intake. The mean total energy intake (TEI) and macronutrient
intakes were calculated using a computerised dietary analysis.
Patients were also asked to record the number of cans of
supplement, or parts thereof, consumed each day. The total
dietary intake was calculated by adding oral supplement con-
sumption to spontaneous food intake. Predicted intakes at baseline
assumed to be the same as predicted TEE on the basis that this is
what would be required to allow weight stability.
Plasma fatty acid analysis
Analysis of EPA in patients’ plasma phospholipids before study
commencement and at 8 weeks was performed by gas chromato-
graphy as described previously (Wigmore et al, 1996). A plasma
EPA level of 1.6% is approximately the 90th percentile in free-
living unsupplemented pancreatic cancer patients (Barber et al,
1999; Zuijdgeest-Van Leeuwen et al, 2002).
Physician-assessed physical function score
Patients were assessed for their level of physical function using the
Karnofsky performance score.
Statistical analysis
The results are expressed as mean (standard error of the mean:
s.e.m.). A Student’s unpaired t-test for independent samples was
used to look for the differences between groups, while a paired
Student’s t-test was used to look for the differences within a
group. Fisher’s exact test and Wilcoxon’s test were used
where appropriate. Differences were considered significant at
Po0.05. A sample size of 16 patients was calculated to detect a
20% difference in PAL between groups with a significance level
of 0.05 and a power of 0.8. The target sample size was increased
to 30 patients to account for possible attrition of patients during
the study.
RESULTS
The characteristics of the 24 patients evaluated at baseline are
shown in Table 1. Patients were elderly (mean age 68), and there
was a preponderance of female subjects. Patients had an average
BMI of 20 and were malnourished having lost, on average, 19%
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of their preillness stable weight. In general, the patients’
Karnofsky score was moderately impaired, indicating that they
were self-caring but unable to carry on normal activities or do
active work.
Patients’ baseline measured and predicted levels of REE, TEE,
EEA and PAL are shown in Table 2. Patients had a significantly
elevated REE when compared with predicted values. Conversely,
their EEA and TEE were significantly lower than predicted.
Patients’ TEIs were significantly lower than predicted values, but
were not significantly different from measured TEE.
Following randomisation of the patients willing to partici-
pate in this extended protocol of the larger trial, 15 patients
were allocated to the control energy and protein dense oral
nutritional supplement and nine patients to the n-3 enriched
oral supplement. The mismatch in sample size was due to
the larger study being stratified and the investigators being
blinded until the study was complete. Patient characteristics
at baseline according to treatment group are shown in Table 3.
There were no significant differences between the groups.
Five patients failed to complete the 8-week period of oral
supplementation. The reasons for sample attrition are shown in
Figure 1.
The baseline meal intake, average oral supplement consumption
and change in total dietary intake over the 8 weeks of the study are
shown in Table 4. No patient reported intake of high n-3 fatty acid
containing foods. The recommended supplement dose was
Table 1 Baseline characteristics of weight-losing patients with unresect-
able pancreatic cancer (n¼ 24)
Baseline characteristics Patients (n¼24)
Sex (M : F) 10 : 14
Age (years) 68 (2)
Stage of disease
II 15
III 4
IV 5
BMI 20 (1)
% weight loss from usual weight 19 (1)
Karnofsky performance score
60 4
70 12
80 5
90 3
Values are mean (s.e.m.) or total number of patients.
Table 2 Comparison of baseline measured and predicted REE, TEE, TEI
and PAL of weight-losing patients with unresectable pancreatic cancer
(n¼ 24)
Measured Predicted P
REE (kcal day1) 1387 (42) 1268 (32) 0.001
TEE(kcal day1) 1732 (82) 1903 (48) 0.023
TEI (kcal day1) 1754 (95) 1903 (48) 0.007
EEA (kcal day1) 345 (60) 634 (16) 0.001
PAL 1.24 (0.04) 1.50 —
Values are mean (s.e.m.), comparisons by Student’s paired t-test.
Table 3 Baseline characteristics of 24 weight-losing patients with unresectable pancreatic cancer randomised to either control or n-3 fatty acid containing
(experimental) sip feed
Control (n¼ 15) Experimental (n¼ 9) P
Sex (M : F) 4 : 11 6 : 3 0.068
Age (years) 70 (3) 65 (2) 0.159
Stage of disease
II 8 7 0.237
III 3 1
IV 4 1
BMI (kg m2) 20 (1) 21 (1) 0.961
% weight loss in previous 6 months 19 (2) 21 (2) 0.500
Karnofsky performance score
60 3 1 0.871
70 6 6
80 5 —
90 1 2
Values are mean (s.e.m.) or total number of patients; comparisons by Student’s t-test, Fisher’s exact or Wilcoxon’s test where appropriate.
Randomised 
N = 24  
Baseline Allocated to  
control group 
n = 15 
Allocated to experimental
group 
n = 9 
Week 8 n = 12 n = 7 
Lost to follow-up 
n = 3 
Lost to follow-up
n = 2 
Death n = 1 n = 1 
Patient  
withdrawal n = 1 n = 0 
Change in  
medical status n = 1 n = 1 
Figure 1 Pattern of randomisation and reasons for sample attrition.
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2 cans day1. The mean intake of the control supplement was
1.5 cans day1 and that of the n-3 fatty acid enriched supplement
was 1.9 cans day1 (P¼ 0.126). An external review of randomisa-
tion procedures confirmed that all patients received the correct
supplement. Compared with baseline intake, energy and protein
intake increased significantly in those randomised to the n-3
enriched supplement. The total energy and protein intake did not
increase significantly in those who received the isocaloric,
isonitrogenous control supplement. Between-group comparisons
revealed a trend towards increased change in TEI and a
significantly greater increase in the total protein intake in those
randomised to the n-3 enriched supplement.
Observed changes in weight, LBM, REE, TEE, EEA and PAL
after 8 weeks of oral supplementation are shown in Table 5.
Compared with baseline values, there were no significant changes
in weight or LBM in either group over the 8-week period of
supplementation. When compared with baseline values, there were
no significant changes in TEE, REE, EEA or PAL in patients
randomised to the control supplement. In contrast, when
compared with baseline values, TEE, EEA and PAL all increased
significantly in those randomised to the n-3 enriched supplement.
There were, however, no statistically significant differences
between groups.
The mean baseline and week 8 plasma EPA levels from patients
in either group completing the 8-week period of oral supplement
consumption are shown in Table 6. At baseline, the levels of EPA
were low and two control patients had levels above the 90th centile
of 1.6% of unsupplemented pancreatic cancer patients (see
Patients and Methods). After 8 weeks, the EPA levels of these
two patients had risen further (2.8 and 3.1%) and two more of
the 12 patients in the control supplement group had levels of
EPA 41.6%, thereby suggesting consumption of EPA from a
source outwith the trial, and indicting noncompliance with the
protocol.
On the basis that four patients taking the control supplement
had high EPA levels, a post hoc analysis based on plasma EPA
levels was undertaken (Table 7), in which these four patients were
considered part of the high EPA group. This analysis revealed
results similar to the ITT analysis. TEE, EEA, REE and PAL
increased significantly from baseline in the ‘high EPA’ group, but
not in those in the low EPA group. In addition, following 8-weeks
supplementation change in TEE was significantly greater
(P¼ 0.018) and there was a trend towards higher EEA (P¼ 0.06)
and PAL (P¼ 0.08) in the ‘high EPA’ group compared with the ‘low
EPA’ patients.
Table 4 Baseline meal intake, average oral nutritional supplement intake
and change in total dietary intake for patients in the experimental and
control groups reaching week 8
Control
(n¼ 12)
Experimental
(n¼ 7) P
Baseline energy intake (meals)
(kcal day1)
1814 (111) 1574 (178) a
Baseline protein intake (meals)
(g protein day1)
73 (4) 57 (7) a
Supplement energy intake
(kcal day1)
461 (56) 576 (44) a
Supplement protein intake
(g protein day1)
24 (3) 30 (2) a
Change in total energy intakeb
(kcal day1)
166 (122) 474 (106) a, c, d
Change in total protein intakeb
(g protein day1)
4 (5) 27 (6) c, d, e
aControl change vs experimental change, P: NS. bThat is, meals plus supplement
intake during week 8 minus baseline meal intake (week 0). cControl change from
baseline, P: NS. dExperimental change from baseline, Po 0.05. eControl change vs
experimental change, Po 0.05. Values are mean (s.e.m.); comparisons by Student’s
t-test for independent samples and comparisons within groups by paired Student’s
t-test.
Table 5 Change (i.e. week 8 minus week 0) in weight,LBM, REE, TEE, EEA and PAL for patients in the experimental and control groups reaching week 8
Control (n¼ 12) Experimental (n¼7) P
Change in weight (kg) 0.2 (0.8) 0.0 (1.3) a,b,d
Change in LBM (kg)e 0.6 (0.8) 0.3 (0.5) a,b,d
Change in REE (kcal day1) 15 (25) 1 (42) a,b,d
Change in TEE (kcal day1) 99 (132) 286 (79) a,c,d
Change in EEA (kcal day1) 114 (131) 287 (66) a,c,d
Change in PAL 0.01 (0.1) 0.18 (0.05) a,c,d
Values are mean (s.e.m.) comparisons between groups by Student’s t-test for independent samples and comparisons within groups by paired Student’s t-test. aControl change
from baseline, P: NS. bExperimental change from baseline, P: NS. cExperimental change from baseline, Po0.05. dControl change vs experimental change, P: NS. eChanges in LBM
calculated from TBW measurements using isotope dilution methodology.
Table 6 Baseline and final plasma phospholipid EPA levels in patients in
the experimental and control groups who completed 8-weeks oral
supplementation
Control
(n¼ 12)
Experimental
(n¼ 7) P
Baseline EPA (%) 0.91 (0.21) 0.94 (0.09) 0.933
Patients (n) with baseline EPA41.6% 2 0 —
Final EPA (%) 1.70 (0.49) 5.57 (0.70) 0.001
Patients (n) with final EPA41.6% 4 7 —
Values are mean (s.e.m.) with comparisons between groups by Student’s t-test for
independent samples.
Table 7 Change (i.e. week 8 minus week 0) in REE, TEE, EEA and PAL
for patients allocated in a pos hoc analysis to either the low or high EPA
groups based on week 8 plasma phospholipid EPA levels
Low EPA group
(n¼ 8)
High EPA group
(n¼ 11)
Change in REE (kcal day1) 55 (23) 23 (30) a,b,c
Change in TEE (kcal day1) 68 (134) 340 (92) a,b.d
Change in EEA (kcal day1) 13 (143) 318 (93) a,b,c
Change in PAL 0.01 (0.10) 0.24 (0.08) a,b,c
Values are mean (s.e.m.); comparisons between groups by Student’s t-test for
independent samples and comparisons within groups by paired Student’s t-test.
aControl change from baseline: NS. bExperimental change from baseline: Po0.05.
cControl change vs experimental change: NS. dControl change vs experimental
change: Po0.05.
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DISCUSSION
The present study demonstrates that in cachectic cancer patients,
REE is increased but that TEE and therefore physical activity is
reduced. These findings confirm previous studies, which have
demonstrated that REE is increased in cachectic patients with
pancreatic cancer (Falconer et al, 1994), and are consistent with
numerous other studies, which have suggested that at least a
proportion of weight-losing cancer patients are hypermetabolic
(Dempsey et al, 1986; Fredrix et al, 1991). Such hypermetabolism
is potentially of great significance to the weight-losing patient.
First of all it may accelerate wasting by increasing any energy
deficit already present due to anorexia. Second, as shown in the
present study, it may be associated with a reduction in PAL. Such
decreased physical activity may represent an adaptive response in
which physical activity is reduced in an attempt to narrow
the deficit between TEI and energy expenditure. Alternatively,
it may reflect a negative effect on physical activity secondary to
the patient’s primary disease process or, indeed, a combination of
the two.
A previous study using a urea-bicarbonate 36 h protocol
in patients with lung cancer (Gibney et al, 1997) has documented
a similar pattern of increased REE and decreased TEE and
PAL. However, not all hypermetabolic patients have reduced
physical activity. For example, Heijligenberg et al (1997) demon-
strated relative hypermetabolism in a group of patients with
HIV infection but observed relatively normal TEE and PAL.
These patients were not wasted or losing weight at the time of
study, and presumably were able to maintain energy balance by
eating slightly more. This tends not to be the case in advanced
cancer where anorexia and early satiety are often dominant
symptoms.
The level of physical activity observed in the present study
was markedly reduced (mean PAL: 1.24) compared with the value
for healthy sedentary adults (PAL: 1.4– 1.5; (Black et al, 1996).
Such a PAL is comparable with that observed in spinal cord-
injured patients living at home (mean PAL: 1.32; Mollinger et al,
1985) or patients with cerebral palsy (mean PAL: 1.23; Stallings
et al, 1996). In the present study, the mean Karnofsky performance
score of the patients was 70, suggesting that they were ‘self-caring
but unable to carry on normal activities or do active work’. The
data from the doubly labelled water studies would certainly
confirm that patients were functioning at or below such a level.
These findings attest to the marked impact of advanced cancer and
cachexia on the physical function and quality of life of such
patients.
In the present study, the patients’ mean baseline calorie intake
from food was 1754 kcal day1. This represented less than what
would be predicted for food intake had such individuals been
healthy (1903 kcal day1: see Table 2), but was roughly equivalent to
measured TEE. From the recall of their preillness stable weight, the
patients had lost approximately 20% of their normal weight,
equivalent to about 2–3 kg month1. However, if their energy
intake matched their energy expenditure, this would suggest either
that the patients’ evident energy deficit (cf previous weight loss) had
become attenuated or that the diet diary method used to measure
food intake had systematically overestimated the patients’ intake.
Previous studies in obese patients have suggested a systematic bias
towards underestimation of food intake in patients undertaking
dietary restriction (Lissner et al, 1998). The findings of the present
study caution against the overinterpretation of diet diary data in
studies where cachectic patients may want to please their physician
or relatives by systematically overestimating their food intake.
Following baseline assessment, patients were randomised to
receive for 8 weeks an energy and protein dense oral supplement
with or without n-3 fatty acids. During the 8 weeks, the patients’
weight and LBM remained stable. However, the net increase in
both protein and energy intake in the patients taking the n-3
enriched supplement (Table 4) seemed to translate into an almost
parallel increase in TEE with a consequent rise in PAL. In contrast,
those receiving the isocaloric, isonitrogenous control supplement
had no significant increase in net intake and no change from
baseline in terms of TEE or PAL. These data are unique in
documenting (with objective methodology) an improvement in the
physical function of cachectic patients with advanced cancer
following institution of combination therapy (i.e. n-3 fatty acids
(EPA) and energy and protein dense oral supplements). A previous
study with this combination regimen (Barber et al, 1999) in
patients with pancreatic cancer demonstrated a similar net rise in
energy intake (400 kcal day1) with no change in fat mass but a
significant improvement in performance status (Karnofsky score).
These findings parallel those of the present study with translation
of extra energy intake into increased physical activity rather than
energy storage. The mechanism for this effect remains unclear but
may relate to the action of EPA on various mediator pathways (e.g.
cytokines or PIF).
In a previous study with the same experimental supplement in
similar patients (Barber et al, 1999), LBM increased significantly
(2 kg in 7 weeks). In the present study, patients’ LBM did not
change significantly. In the overall randomised trial (of which the
present study was a part), compliance with the experimental
supplement averaged 1.4 cans day1 (Fearon et al, 2003), which
was less than in the study by Barber et al (1999) or in the present
substudy (both 1.9 cans day1). Equally, LBM did not change
significantly in the overall trial although there was a positive,
direct, significant relationship between supplement intake and
change in LBM in the experimental group but not in the control
(Fearon et al, 2003). It is therefore not clear whether the increased
TEE and PAL documented in the present study is necessarily
accompanied by an increase in the mass rather than in the
function/quality of the LBM. This observation raises the issue of
whether trials in the treatment of cancer cachexia should focus
exclusively on nutritional rather than functional end points.
In the present study, analysis of the patients’ plasma EPA
at week 8 revealed strong evidence that some of the control
subjects had been taking an exogenous source of EPA. When
the results were reanalysed on the basis of plasma EPA levels, the
same trends observed in the ITT analysis were observed and
some became more obvious. However, such post hoc analysis
has to be treated with caution and will require confirmation
in further studies. The numbers of patients included in the
present study was relatively small and fell slightly short of the
intended recruitment. Analysis was further hampered by the
randomisation process allocating more patients to the control
group compared with the experimental group. Nevertheless,
the present study provides pilot data, which suggest that in
contrast to an isocaloric, isonitrogenous control nutritional
supplement, administration of a supplement enriched with
n-3 fatty acids results in an increase in PAL. Further work is
required to confirm these results and clarify the relationship
between PAL and overall quality of life. Documentation of TEE
and PAL using the DLW technique is labour intensive and
costly. However, the data obtained are unique and highlight the
potential of such objective methodology to provide a focus
for therapeutic intervention in the complex syndrome of cancer
cachexia.
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